U.S. will exempt U.K.-origin pharma and related products from Section 232 tariffs under a new bilateral pricing agreement.

Regulatory Briefing: U.S.–U.K. Pharmaceutical Pricing Agreement and Section 232 Tariff Exemption

1. What changed

• The United States and the United Kingdom have reached an agreement in principle on pharmaceutical pricing as part of the U.S.–U.K. Economic Prosperity Deal (EPD).
• As part of this agreement, the United States has committed to:
• Exempt U.K.-origin pharmaceuticals, pharmaceutical ingredients, and medical technology from Section 232 tariffs; and
• Refrain from targeting U.K. pharmaceutical pricing practices in any future Section 301 investigation for the duration of President Trump’s term.
• The announcement is policy-level; specific HTS/Chapter 99 implementation details and any formal proclamations or Federal Register notices are not included in the text provided and will need to be monitored.

2. Affected products

The agreement explicitly covers U.K.-origin:

• Pharmaceuticals (finished drug products)
• Pharmaceutical ingredients (e.g., active pharmaceutical ingredients (APIs), intermediates)
• Medical technology (likely including certain medical devices and related equipment)

While no specific HTS codes are listed in the announcement, the following broad HTS chapters/headings are likely implicated for U.K.-origin goods where Section 232 tariffs currently apply or could apply:

• Chapter 29: Organic chemicals (including many APIs and intermediates)
• Chapter 30: Pharmaceutical products (finished dosage forms, bulk medicines)
• Chapter 90: Medical devices and instruments (medical technology)

Importers should:

• Identify all products sourced from the United Kingdom that fall under Chapters 29, 30, and 90, and any other headings currently subject to Section 232 duties.
• Confirm that the country of origin under U.S. rules of origin is the United Kingdom (not merely shipped from the U.K.).

3. Rate changes (tariff impact)

• The announcement states that U.K.-origin pharmaceuticals, pharmaceutical ingredients, and medical technology will be exempt from Section 232 tariffs.
• Section 232 tariffs are typically applied as additional ad valorem duties (e.g., 10%, 25%) via Chapter 99 HTS provisions.
• The text does not specify the exact Section 232 rates currently applied to the covered U.K.-origin products, nor the precise Chapter 99 subheadings that will be modified.

Expected impact:

• Old rate: MFN base duty rate + applicable Section 232 additional duty (for example, base rate X% + 25% under a Section 232 Chapter 99 provision, where applicable).
• New rate for qualifying U.K.-origin products: MFN base duty rate only (Section 232 additional duty reduced from its current rate—e.g., 10% or 25%—to 0% for these products), once implementing measures take effect.

Because the announcement is high-level, importers must wait for:

• A Presidential Proclamation or other formal legal instrument implementing the exemption; and
• CBP/HTS instructions (likely via Federal Register and CSMS) specifying:
• Which HTS subheadings are covered;
• Which Chapter 99 provisions are amended or newly created; and
• The effective date and any retroactivity.

4. Dates

From the announcement:

• The agreement is described as an “agreement in principle” and is tied to the U.S.–U.K. Economic Prosperity Deal.
• The U.S. commitment to refrain from targeting U.K. pharmaceutical pricing practices in any future Section 301 investigation is stated to apply “for the duration of President Trump’s term.”

Missing/To be confirmed:

• Effective date for the Section 232 tariff exemption on U.K.-origin pharmaceuticals, ingredients, and medical technology.
• Whether the exemption will apply retroactively to entries on or after a specified date.
• Any sunset or review date for the Section 232 exemption itself.

Compliance teams should:

• Monitor the Federal Register and USTR/White House announcements for the implementing action and effective date.
• Watch for CBP Cargo Systems Messaging Service (CSMS) notices providing operational guidance.

5. Required actions for importers, brokers, and compliance teams

A. Product and origin mapping

• Compile a list of all imported products that:
• Are sourced from the United Kingdom; and
• Fall within pharmaceutical products, pharmaceutical ingredients, or medical technology.
• Confirm U.S. country-of-origin determinations for these products under applicable rules (substantial transformation, etc.). Only goods with U.K. origin will qualify for the exemption.

B. HTS classification review

• Review current HTS classifications for:
• APIs and intermediates (primarily Chapter 29);
• Finished pharmaceuticals (Chapter 30);
• Medical devices and related technology (Chapter 90 and possibly other chapters, depending on the product).
• Identify which of these HTS codes are currently subject to Section 232 additional duties via Chapter 99 provisions.

C. Prepare for duty calculation changes

• Once the implementing measure is issued:
• Update internal duty rate tables and broker instructions to remove Section 232 additional duties for qualifying U.K.-origin products.
• Ensure that the correct Chapter 99 codes (if any remain applicable) are used or removed as instructed by CBP.
• Coordinate with customs brokers to:
• Stop applying Section 232 Chapter 99 provisions to qualifying U.K.-origin entries as of the effective date; and
• Correct any automated broker systems that may default to applying Section 232 duties based on HTS alone without origin logic.

D. Post-entry and reconciliation strategy

• If the exemption is implemented with retroactive effect:
• Identify entries of qualifying U.K.-origin products that paid Section 232 duties during the retroactive period.
• Plan to file Post Summary Corrections (PSCs), protests, or reconciliation entries, as applicable, to recover overpaid duties.
• Maintain documentation supporting:
• U.K. origin (supplier declarations, manufacturing records, bills of materials, etc.);
• Correct HTS classification; and
• Eligibility for the exemption under the final legal text.

E. Contracting and pricing

• Review purchase and sales contracts that currently factor in Section 232 duties on U.K.-origin pharmaceuticals, ingredients, or medical technology.
• Consider revising pricing, landed cost models, and customer quotations to reflect the removal of Section 232 duties once effective.

F. Risk and policy monitoring

• Track any subsequent U.S. actions that could:
• Modify or revoke the Section 232 exemption; or
• Introduce other trade remedies (e.g., antidumping/countervailing duties, safeguards) on similar products.
• Note that while the U.S. has committed not to target U.K. pharmaceutical pricing practices in a Section 301 investigation during President Trump’s term, this does not preclude other types of trade actions or future changes under a different administration.

6. References and where to find implementation details

Primary policy announcement (USTR):

• The text provided appears to be a press release from the Office of the U.S. Trade Representative (USTR) announcing the agreement in principle on pharmaceutical pricing with the United Kingdom.
• For the official posting and any related documents, monitor:
• USTR press releases: https://ustr.gov/about-us/policy-offices/press-office/press-releases
• USTR homepage: https://ustr.gov/

Implementation and legal instruments (expected):

• Federal Register (for Presidential Proclamations or USTR/Commerce/HHS implementing notices):
• https://www.federalregister.gov/
• White House or Presidential documents (for Section 232-related proclamations):
• https://www.whitehouse.gov/briefing-room/
• U.S. Customs and Border Protection (CBP) operational guidance:
• CSMS messages: https://www.cbp.gov/trade/automated/cargo-systems-messaging-service
• CBP trade page: https://www.cbp.gov/trade

HTS and duty rate references:

• Harmonized Tariff Schedule of the United States (HTSUS):
• https://hts.usitc.gov/
• For Chapter 99 and Section 232 provisions, consult the latest HTSUS edition and any supplements.

7. Key takeaways

• The agreement in principle commits the U.S. to exempt U.K.-origin pharmaceuticals, pharmaceutical ingredients, and medical technology from Section 232 tariffs, which will reduce or eliminate additional duties on qualifying imports once implemented.
• No specific HTS codes, Chapter 99 provisions, or effective dates are provided in the announcement; importers must closely monitor subsequent legal and CBP guidance.
• Importers and brokers should proactively map affected products, confirm U.K. origin, and prepare systems and processes to adjust duty calculations and seek refunds if retroactivity is granted once the exemption is formally in place.